Alzheimer's Disease: Epidemiology and Clinical Progression.
Alzheimer's Disease: Epidemiology and Clinical Progression.
复制标题
DOI：
10.1007/s40120-022-00338-8
复制
发表时间：
2022-06
影响因子：
3.7
通讯作者：
Zhang, Quanwu
中科院分区：
文献类型：
--
作者：
Monfared, Amir Abbas Tahami;Byrnes, Michael J.;White, Leigh Ann;Zhang, Quanwu
关键词：
阿尔茨海默病（AD）在全世界流行，并且是老年人（年龄≥ 65岁）痴呆的主要原因。为了更深入地了解AD流行病学及其进展的最新文献，我们对北美，欧洲和亚洲的PubMed索引文献（2014-2021）进行了综述。AD的患病率、发病率和死亡率的上升证明了AD的全球死亡率，由于AD的诊断不足，AD的估计值很低。由AD引起的轻度认知障碍（MCI）最终可进展为AD痴呆; MCI患者中AD痴呆病因的估计范围为40%至75%，这取决于研究的人群以及MCI诊断是在临床上还是与生物标志物结合进行的。AD痴呆的风险随着从无淀粉样蛋白β（Aβ）积累的正常认知到早期神经变性和随后的MCI的进展而增加。对于Aβ蓄积和神经变性患者，AD痴呆的终生风险估计为女性41.9%，男性33.6%。关于从临床前AD进展到MCI的数据很少，但对三个临床前国家老龄化研究所和阿尔茨海默病协会（NIA-AA）阶段的进展进行的分析表明，NIA-AA 3期（AD生物标志物阳性的轻微认知下降）可能与其他治疗决策工具结合使用。显示风险增加的因素包括较低的简易精神状态检查（MMSE）评分、较高的阿尔茨海默病评估量表（ADAS-cog）评分、阳性APOE 4状态、白色高信号体积、内嗅皮质萎缩、脑脊液（CSF）总tau蛋白、CSF神经颗粒素水平、工具性日常生活活动（IADL）依赖性和女性。结果表明，随着新的疾病修饰疗法的引入，生物标志物与神经认知测试的结合使用将成为临床实践的重要组成部分。
Alzheimer’s disease (AD) is prevalent throughout the world and is the leading cause of dementia in older individuals (aged ≥ 65 years). To gain a deeper understanding of the recent literature on the epidemiology of AD and its progression, we conducted a review of the PubMed-indexed literature (2014–2021) in North America, Europe, and Asia. The worldwide toll of AD is evidenced by rising prevalence, incidence, and mortality due to AD—estimates which are low because of underdiagnosis of AD. Mild cognitive impairment (MCI) due to AD can ultimately progress to AD dementia; estimates of AD dementia etiology among patients with MCI range from 40% to 75% depending on the populations studied and whether the MCI diagnosis was made clinically or in combination with biomarkers. The risk of AD dementia increases with progression from normal cognition with no amyloid-beta (Aβ) accumulation to early neurodegeneration and subsequently to MCI. For patients with Aβ accumulation and neurodegeneration, lifetime risk of AD dementia has been estimated to be 41.9% among women and 33.6% among men. Data on progression from preclinical AD to MCI are sparse, but an analysis of progression across the three preclinical National Institute on Aging and Alzheimer’s Association (NIA-AA) stages suggests that NIA-AA stage 3 (subtle cognitive decline with AD biomarker positivity) could be useful in combination with other tools for treatment decision-making. Factors shown to increase risk include lower Mini-Mental State Examination (MMSE) score, higher Alzheimer’s Disease Assessment Scale (ADAS-cog) score, positive APOE4 status, white matter hyperintensities volume, entorhinal cortex atrophy, cerebrospinal fluid (CSF) total tau, CSF neurogranin levels, dependency in instrumental activities of daily living (IADL), and being female. Results suggest that use of biomarkers alongside neurocognitive tests will become an important part of clinical practice as new disease-modifying therapies are introduced.
登录
查看更多内容
中国阿尔茨海默病和帕金森病的患病率：最新系统分析
影响因子：
4.8
作者：
Cui L;Hou NN;Wu HM;Zuo X;Lian YZ;Zhang CN;Wang ZF;Zhang X;Zhu JH
通讯作者：
Zhu JH
影响因子：
3.3
作者：
Harada CN;Natelson Love MC;Triebel KL
通讯作者：
Triebel KL
DOI：
10.3233/jad-150852
发表时间：
2016
期刊：
Journal of Alzheimer's disease : JAD
影响因子：
--
作者：
Henneges C;Reed C;Chen YF;Dell'Agnello G;Lebrec J
通讯作者：
Lebrec J
影响因子：
2.1
作者：
Canevelli, Marco;Kelaiditi, Eirini;Cesari, Matteo
通讯作者：
Cesari, Matteo
DOI：
10.1016/j.jalz.2016.01.011
发表时间：
2016-07
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Green C;Zhang S
通讯作者：
Zhang S